Pipeline

TLY012

TLY012 is a trimeric recombinant human TRAIL designed to selectively induce apoptosis in activated myofibroblasts, the key driver of multiple fibrotic diseases, through DR5-mediated apoptotic pathways. This targeted approach addresses the underlying cause of fibrosis, offering a novel therapeutic strategy for treating fibrotic conditions.

Do you have any questions for Theraly Fibrosis?

For questions regarding our current Development stage, Please Contact [email protected]